COVID-19 is Associated with an Acquired Factor XIII Deficiency
Coronavirus disease 2019 (COVID-19) is associated with an increased risk of thrombotic complications. Multiple lines of evidence support the existence of a hypercoagulable state in hospitalized COVID-19 patients. Enhanced platelet activation, enhanced in vivo thrombin generation and ex vivo thrombin-generating capacity, hyperfibrinogenaemia, and ex vivo resistance to fibrinolysis have all been demonstrated.
Authors
- Charlotte Thålin (ORCID: https://orcid.org/0000-0002-1345-6491)
- Fien A. von Meijenfeldt (ORCID: https://orcid.org/0000-0003-0274-2414)
- Annika Lundström (ORCID: https://orcid.org/0000-0003-1671-0827)
- Sebastian Havervall (ORCID: https://orcid.org/0000-0003-1671-8183)
- Jelle Adelmeijer (ORCID: https://orcid.org/0000-0003-3693-2750)
- Ton Lisman (ORCID: https://orcid.org/0000-0002-3503-7140)
- Nigel Mackman (ORCID: https://orcid.org/0000-0002-9170-7700)
- Maria Magnusson (ORCID: https://orcid.org/0000-0001-5388-6608)
Institutions
- University of North Carolina at Chapel Hill (US)
Publication Details
- Journal
- UNC Libraries
- Published
- 2025-05-20
- DOI
- https://doi.org/10.17615/nege-xd13
- Primary Topic
- Blood properties and coagulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00